<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55391">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988532</url>
  </required_header>
  <id_info>
    <org_study_id>HAEM-4073</org_study_id>
    <secondary_id>U1111-1138-3464</secondary_id>
    <nct_id>NCT01988532</nct_id>
  </id_info>
  <brief_title>Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia</brief_title>
  <official_title>Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in the United States of America (USA). The aim of the study is to
      assess the impact of pain on functional impairment and quality of life in adult persons with
      hemophilia (PWH) with and without inhibitors with joint bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Prevalence of acute (bleed-related) pain (percentage)</measure>
    <time_frame>At the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of chronic (arthritic) pain (percentage)</measure>
    <time_frame>At the first visit (only one study visit)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia A With Inhibitors</condition>
  <condition>Haemophilia B</condition>
  <condition>Haemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>Adult PWH</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Subject will only fill out a questionnaire</description>
    <arm_group_label>Adult PWH</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive adult PWH in the United States of America (USA) willing to consent to
        participation who have any history of joint bleeding or joint pain presenting for a
        comprehensive care visit during which joint range of motion will be assessed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males able to provide consent and complete a survey in English

          -  Congenital hemophilia A or B with or without inhibitors with any history of joint
             bleeding or joint pain

          -  Presentation at the treatment center for a comprehensive annual visit where joint
             range of motion will be obtained

          -  Informed consent obtained before any study-related activities. (Study-related
             activities are any procedure related to recording of data according to the protocol)

        Exclusion Criteria:

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>October 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
